Published in Gene Therapy Weekly, November 6th, 1995
The agreement provides Aastrom with a partner to accelerate the development of the automated Aastrom CPS for lymphoid cell and gene therapies. This market includes patients with AIDS, cancer and other immune disorders.
The agreement gives RPR rights to use and sell Aastrom technology and products on a worldwide basis with potential to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.